Harvard Health Publishing: Men with intermediate-risk prostate cancer may benefit from undergoing androgen-deprivation therapy (ADT).
![](https://static.wixstatic.com/media/a24c3d_2e017c5b8ed24f57932221a815ff5cc4~mv2.jpg/v1/fill/w_724,h_483,al_c,q_80,enc_auto/a24c3d_2e017c5b8ed24f57932221a815ff5cc4~mv2.jpg)
Men with intermediate-risk prostate cancer may benefit from undergoing androgen-deprivation therapy (ADT) depending on how far the cancer has progressed, says a study published online Sept. 9, 2020, by JAMA Network Open. The results could help men better weigh risk versus reward when choosing their prostate cancer treatment options. READ MORE
(Source: Harvard Health Publishing, 12/01/2020)
Comments